Notice of Charter Renewal: Advisory Committee on the Medical Uses of Isotopes, 17529-17530 [2012-7184]

Download as PDF 17529 Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Notices APPENDIX—Continued [19 TAA petitions instituted between 3/5/12 and 3/9/12] TA–W Subject firm (petitioners) Location 81397 ................ Blue Scope Buildings (HCI Steel Division) (State/OneStop). Pratt & Whitney (State/One-Stop) ........................................ Gerber Scientific, Inc., Information Technology Department (Company). North American Communications, Inc. (Company) .............. J.P. Morgan Clearing Corp (State/One-Stop) ...................... Conesys (Company) ............................................................. Huitt Mills, Inc. (Company) ................................................... Jones Distribution Corporation (Company) .......................... Lumber Products Millwork & Components Division (Company). PCCW Teleservices (U.S.), Inc. (Workers) .......................... Arlington, WA ........................ 03/06/12 03/05/12 East Hartford, CT .................. Tolland, CT ........................... 03/06/12 03/06/12 03/05/12 03/05/12 Duncansville, PA ................... Brooklyn, NY ......................... Torrance, CA ......................... North Wilkesboro, NC ........... Lawrenceburg, TN ................ Tualatin, OR .......................... 03/06/12 03/07/12 03/08/12 03/08/12 03/09/12 03/09/12 02/24/12 03/06/12 02/20/12 03/07/12 03/08/12 02/27/12 Tiffin, OH ............................... 03/09/12 03/08/12 81398 ................ 81399 ................ 81400 81401 81402 81403 81404 81405 ................ ................ ................ ................ ................ ................ 81406 ................ [FR Doc. 2012–7167 Filed 3–23–12; 8:45 am] BILLING CODE 4510–FN–P LEGAL SERVICES CORPORATION Request for Comments—Financial Eligibility Screening and Online Intake Legal Services Corporation. Notice; request for comments. AGENCY: ACTION: The Legal Services Corporation seeks public comment on a draft program letter discussing minimum screening requirements for LSC recipients to apply when determining financial eligibility of applicants based on information collected through online systems. DATES: Written comments will be accepted until April 25, 2012. ADDRESSES: Written comments may be submitted by mail, fax or email to Mark Freedman, Senior Assistant General Counsel, Legal Services Corporation, 3333 K St. NW., Washington, DC 20007; 202–295–1623 (phone); 202–337–6519 (fax); mfreedman@lsc.gov. FOR FURTHER INFORMATION CONTACT: Mark Freedman, Senior Assistant General Counsel, Legal Services Corporation, 3333 K St. NW., Washington, DC 20007; 202–295–1623 (phone); 202–337–6519 (fax); mfreedman@lsc.gov. SUMMARY: The Legal Services Corporation (‘‘LSC’’ or ‘‘Corporation’’) was established by the United States Congress ‘‘for the purpose of providing financial support for legal assistance in noncriminal matters or proceedings to persons financially unable to afford such assistance.’’ 42 U.S.C. 2996b(a). LSC performs this function primarily through providing federal funding to civil legal aid programs providing legal services to tkelley on DSK3SPTVN1PROD with NOTICES SUPPLEMENTARY INFORMATION: VerDate Mar<15>2010 19:32 Mar 23, 2012 Jkt 226001 low-income persons throughout the United States and its possessions and territories in geographic areas determined by LSC. Each LSC recipient must screen all applicants for LSC funded legal assistance to determine if they meet the recipient’s financial eligibility requirements, which themselves must comply with the LSC financial eligibility requirements set forth at 45 CFR part 1611. Over the last several years, LSC has seen a marked increase in the number of LSC grant recipients implementing online systems as part of their clienteligibility screening systems to improve efficiency in their intake processes. LSC has received a corresponding increase in compliance-related inquiries pertaining to these systems. LSC has prepared this draft program letter to assist LSC recipients in complying with eligibility screening requirements for all methods of intake, including online intake systems. It reflects LSC’s obligation to ensure compliance with statutory and regulatory requirements governing the use of LSC funds, as well as LSC’s recognition of the realities of practices in the field. The draft program letter can be found in the ‘‘Matters for Comment’’ section of LSC’s Web site at: https://www.lsc.gov/ about/matters-comment. LSC recognizes the importance of input from the public and from LSC recipients. It is LSC’s intention that the Program Letter balance recognition of the advancements in technology with LSC’s obligation to ensure compliance with the statutory and regulatory requirements governing the use of LSC funds. LSC encourages all interested parties and program staff whose work involves screening applicants to review the draft Program Letter and provide input to LSC. Interested parties may submit comments to LSC within thirty PO 00000 Frm 00128 Fmt 4703 Sfmt 4703 Date of institution Date of petition (30) days of the date of publication of this notice. Dated: March 20, 2012. Victor M. Fortuno, Vice President & General Counsel. [FR Doc. 2012–7117 Filed 3–23–12; 8:45 am] BILLING CODE 7050–01–P NUCLEAR REGULATORY COMMISSION Notice of Charter Renewal: Advisory Committee on the Medical Uses of Isotopes U.S. Nuclear Regulatory Commission. ACTION: This notice is to announce the renewal of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) for a period of two years. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) has determined that the renewal of the Charter for the Advisory Committee on the Medical Uses of Isotopes for the two year period commencing on March 14, 2012 is in the public interest, in connection with duties imposed on the Commission by law. This action is being taken in accordance with the Federal Advisory Committee Act, after consultation with the Committee Management Secretariat, General Services Administration. The purpose of the ACMUI is to provide advice to NRC on policy and technical issues that arise in regulating the medical use of byproduct material for diagnosis and therapy. Responsibilities include providing guidance and comments on current and proposed NRC regulations and regulatory guidance concerning medical use; evaluating certain non-routine uses of byproduct material for medical use; SUPPLEMENTARY INFORMATION: E:\FR\FM\26MRN1.SGM 26MRN1 17530 Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Notices and evaluating training and experience of proposed authorized users. The members are involved in preliminary discussions of major issues in determining the need for changes in NRC policy and regulation to ensure the continued safe use of byproduct material. Each member provides technical assistance in his/her specific area(s) of expertise, particularly with respect to emerging technologies. Members also provide guidance as to NRC’s role in relation to the responsibilities of other Federal agencies as well as of various professional organizations and boards. Members of this Committee have demonstrated professional qualifications and expertise in both scientific and non-scientific disciplines including nuclear medicine; nuclear cardiology; radiation therapy; medical physics; nuclear pharmacy; State medical regulation; patient’s rights and care; health care administration; and Food and Drug Administration regulation. FOR FURTHER INFORMATION CONTACT: Ashley Cockerham, Office of Federal and State Materials and Environmental Management Programs, U.S. Nuclear Regulatory Commission, Washington, DC 20555; Telephone (240) 888–7129; email Ashley.Cockerham@nrc.gov. Dated: March 19, 2012. Andrew L. Bates, Federal Advisory Committee Management Officer. [FR Doc. 2012–7184 Filed 3–23–12; 8:45 am] BILLING CODE 7590–01–P SECURITIES AND EXCHANGE COMMISSION Proposed Collection; Comment Request Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of Investor Education and Advocacy, Washington, DC 20549–0213. tkelley on DSK3SPTVN1PROD with NOTICES Extension: Rule 23c–1, SEC File No. 270–253, OMB Control No. 3235–0260. Notice is hereby given that, pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520), the Securities and Exchange Commission (the ‘‘Commission’’) is soliciting comments on the collection of information summarized below. The Commission plans to submit this existing collection of information to the Office of Management and Budget for extension and approval. VerDate Mar<15>2010 19:32 Mar 23, 2012 Jkt 226001 Rule 23c–1 (17 CFR 270.23c–1) under the Investment Company Act of 1940 (15 U.S.C. 80a), among other things, permits a closed-end fund to repurchase its securities for cash if in addition to the other requirements set forth in the rule: (i) Payment of the purchase price is accompanied or preceded by a written confirmation of the purchase; (ii) the asset coverage per unit of the security to be purchased is disclosed to the seller or his agent; and (iii) if the security is a stock, the fund has, within the preceding six months, informed stockholders of its intention to purchase stock. Commission staff estimates that approximately 29 closed-end funds rely on Rule 23c–1 annually to undertake 261 repurchases of their securities. Commission staff estimates that, on average, a fund spends 2.5 hours to comply with the paperwork requirements listed above each time it undertakes a security repurchase under the rule. Commission staff thus estimates the total annual burden of the rule’s paperwork requirements is 653 hours. In addition, the fund must file with the Commission a copy of any written solicitation to purchase securities given by or on behalf of the fund to 10 or more persons. The copy must be filed as an exhibit to Form N–CSR (17 CFR 249.331 and 274.128). The burden associated with filing Form N–CSR is addressed in the submission related to that form. The estimate of average burden hours is made solely for the purposes of the Paperwork Reduction Act, and is not derived from a comprehensive or even a representative survey or study of the costs of Commission rules and forms. Written comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the Commission, including whether the information has practical utility; (b) the accuracy of the Commission’s estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted in writing within 60 days of this publication. Please direct your written comments to Thomas Bayer, Director/Chief Information Officer, Securities and Exchange Commission, c/o Remi PavlikSimon, 6432 General Green Way, Alexandria, VA 22312; or send an email to: PRA_Mailbox@sec.gov. PO 00000 Frm 00129 Fmt 4703 Sfmt 4703 Dated: March 20, 2012. Kevin M. O’Neill, Deputy Secretary. [FR Doc. 2012–7135 Filed 3–23–12; 8:45 am] BILLING CODE 8011–01–P SECURITIES AND EXCHANGE COMMISSION [Release No. 34–66624] Order Granting an Application of Edward Jones & Co. LLP Exemption From Exchange Act Section 11(d)(1) Pursuant to Exchange Act Section 36(a) March 20, 2012. By letter dated December 5, 2011, counsel for Edward Jones & Co., L.P. (‘‘Edward Jones’’) requested that the Securities and Exchange Commission (‘‘Commission’’) issue to Edward Jones an exemption from Section 11(d)(1) of the Securities Exchange Act of 1934 (‘‘Exchange Act’’) pursuant to Section 36(a) of the Exchange Act. Specifically, the letter requested that the Commission exempt Edward Jones from the prohibitions of Section 11(d)(1) of the Exchange Act if Edward Jones extends to a customer margin on newlypurchased shares of mutual funds not managed or sponsored by Edward Jones or any affiliate of Edward Jones (‘‘nonproprietary mutual funds’’) in instances in which the customer makes a dollarfor-dollar substitution by selling an already-margined non-proprietary mutual fund and buying another nonproprietary mutual fund on margin without incurring any fees, commissions or other costs for the transactions and without Edward Jones otherwise charging the respective customers any fees, commissions or other costs to effect the transactions. We find that it is appropriate and in the public interest and consistent with the protection of investors to grant Edward Jones a conditional exemption from Section 11(d)(1) of the Exchange Act. Conclusion It is hereby ordered, pursuant to Section 36(a) of the Exchange Act, that Edward Jones, based on the representations and the facts presented in its letter and subject to the conditions contained in this order, is exempt from the new issue lending restriction of Section 11(d)(1) of the Exchange Act to the extent that Edward Jones extends to a customer margin on newly-purchased shares of non-proprietary mutual funds in instances in which the customer makes a dollar-for-dollar substitution by selling an already-margined non- E:\FR\FM\26MRN1.SGM 26MRN1

Agencies

[Federal Register Volume 77, Number 58 (Monday, March 26, 2012)]
[Notices]
[Pages 17529-17530]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-7184]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION


Notice of Charter Renewal: Advisory Committee on the Medical Uses 
of Isotopes

AGENCY: U.S. Nuclear Regulatory Commission.

ACTION: This notice is to announce the renewal of the Advisory 
Committee on the Medical Uses of Isotopes (ACMUI) for a period of two 
years.

-----------------------------------------------------------------------

SUPPLEMENTARY INFORMATION: The U.S. Nuclear Regulatory Commission (NRC) 
has determined that the renewal of the Charter for the Advisory 
Committee on the Medical Uses of Isotopes for the two year period 
commencing on March 14, 2012 is in the public interest, in connection 
with duties imposed on the Commission by law. This action is being 
taken in accordance with the Federal Advisory Committee Act, after 
consultation with the Committee Management Secretariat, General 
Services Administration.
    The purpose of the ACMUI is to provide advice to NRC on policy and 
technical issues that arise in regulating the medical use of byproduct 
material for diagnosis and therapy. Responsibilities include providing 
guidance and comments on current and proposed NRC regulations and 
regulatory guidance concerning medical use; evaluating certain non-
routine uses of byproduct material for medical use;

[[Page 17530]]

and evaluating training and experience of proposed authorized users. 
The members are involved in preliminary discussions of major issues in 
determining the need for changes in NRC policy and regulation to ensure 
the continued safe use of byproduct material. Each member provides 
technical assistance in his/her specific area(s) of expertise, 
particularly with respect to emerging technologies. Members also 
provide guidance as to NRC's role in relation to the responsibilities 
of other Federal agencies as well as of various professional 
organizations and boards.
    Members of this Committee have demonstrated professional 
qualifications and expertise in both scientific and non-scientific 
disciplines including nuclear medicine; nuclear cardiology; radiation 
therapy; medical physics; nuclear pharmacy; State medical regulation; 
patient's rights and care; health care administration; and Food and 
Drug Administration regulation.

FOR FURTHER INFORMATION CONTACT: Ashley Cockerham, Office of Federal 
and State Materials and Environmental Management Programs, U.S. Nuclear 
Regulatory Commission, Washington, DC 20555; Telephone (240) 888-7129; 
email Ashley.Cockerham@nrc.gov.

    Dated: March 19, 2012.
Andrew L. Bates,
Federal Advisory Committee Management Officer.
[FR Doc. 2012-7184 Filed 3-23-12; 8:45 am]
BILLING CODE 7590-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.